{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:51:59Z","timestamp":1793350319500,"version":"4.5.0"},"reference-count":130,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["jme.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Over the last decade, there has been a shift in the focus of cancer therapy from conventional cytotoxic drugs to therapies more specifically directed to cancer cells. These novel therapies include immunotherapy, targeted therapy and precision medicine, each developed in great part with a goal of limiting collateral destruction of normal tissues, while enhancing tumor destruction. Although this approach is sound in theory, even new, specific therapies have some undesirable, \u2018off target effects\u2019, in great part due to molecular pathways shared by neoplastic and normal cells. One such undesirable effect is hyperglycemia, which results from either the loss of immune tolerance and autoimmune destruction of pancreatic \u03b2-cells or dysregulation of the insulin signaling pathway resulting in insulin resistance. These distinct pathogenic mechanisms lead to clinical presentations similar to type 1 (T1DM) and type 2 (T2DM) diabetes mellitus. Both types of diabetes have been reported in patients across clinical trials, and data on the mechanism(s) for developing hyperglycemia, prevalence, prognosis and effect on cancer mortality is still emerging. With the rapidly expanding list of clinical indications for new cancer therapies, it is essential to understand the impact of their adverse effects. In this review, we focus on hyperglycemia and diabetes related to cancer therapies, describe what is known about mechanism(s) leading to dysregulated glucose metabolism and provide a guide to management of complex oncology patients with a new diagnosis of diabetes.<\/jats:p>","DOI":"10.1530\/jme-18-0002","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T11:57:26Z","timestamp":1544529446000},"page":"R187-R199","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-6","source":"Crossref","is-referenced-by-count":33,"title":["Novel cancer therapies and their association with diabetes"],"prefix":"10.1530","volume":"62","author":[{"given":"Afreen Idris","family":"Shariff","sequence":"first","affiliation":[{"name":"1Division of Endocrinology, Metabolism and Nutrition, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail","family":"Syed","sequence":"additional","affiliation":[{"name":"2Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A","family":"Shelby","sequence":"additional","affiliation":[{"name":"3Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Force","sequence":"additional","affiliation":[{"name":"4Division of Medical Oncology, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Melson","family":"Clarke","sequence":"additional","affiliation":[{"name":"4Division of Medical Oncology, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Alessio","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Metabolism and Nutrition, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Corsino","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology, Metabolism and Nutrition, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref811","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1074-7613(00)80392-1","article-title":"The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD","volume":"7","year":"1997","journal-title":"Immunity"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2119\/2005-00029.Saltiel","article-title":"Insulin signaling and the regulation of glucose transport","volume":"10","year":"2004","journal-title":"Molecular Medicine"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combinationof everolimus with trastuzumab plus paclitaxel as first-line treatment for patients withHER2- positive advanced breast cancer (BOLERO-1): a phase 3, randomised, doubleblind, multicentre trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1073\/pnas.0803047105","article-title":"Disruption of Tsc2 in pancreatic beta cellsinduces beta cell mass expansion and improved glucose tolerance in a TORC1-dependentmanner","volume":"105","year":"2008","journal-title":"PNAS"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiology","volume":"4","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","year":"2002","journal-title":"European Journal of Endocrinology"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1078155210378913","article-title":"Effect of the tyrosinekinaseinhibitors (sunitinib, sorafenib, dasatinib, andimatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice","volume":"17","year":"2011","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd4476","article-title":"The immune checkpoint inhibitors: where are we now?","volume":"13","year":"2014","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreaticneuroendocrine","volume":"364","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2004-0921","article-title":"Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance","volume":"146","year":"2005","journal-title":"Endocrinology"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MOT.0b013e32835a4be2","article-title":"Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use","volume":"17","year":"2012","journal-title":"Current Opinion in Organ Transplantation"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040620715625966","article-title":"The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia","volume":"7","year":"2016","journal-title":"Therapeutic Advances in Hematology"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/db07-0922","article-title":"mTOR inhibition by rapamycin prevents betacelladaptation tohyperglycemia and exacerbates the metabolic state in type 2 diabetes","volume":"57","year":"2008","journal-title":"Diabetes"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12032-013-0805-3","article-title":"Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer","volume":"31","year":"2014","journal-title":"Medical Oncology"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00125-005-1886-0","article-title":"Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signaling and the effects of a selective glycogen synthase kinase-3 inhibitor","volume":"48","year":"2005","journal-title":"Diabetologia"},{"key":"ref51","first-page":"173","article-title":"Incidence of endocrine dysfunction following the use of different inhibitor regimens: a systematic review and meta-analysis","volume":"4","year":"2018","journal-title":"JAMA"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2009.04.003","article-title":"The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review","volume":"156","year":"2009","journal-title":"Regulatory Peptides"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with the use of mTOR inhibitors for cancer therapy","volume":"40","year":"2014","journal-title":"Cancer Treatment Reviews"},{"key":"ref931","first-page":"2015","article-title":"Precipitation of autoimmune diabetes with anti immunotherapy","journal-title":"Diabetes Care"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA\u20114andanti\u2011PD\u20111antibodies alone and in combination","volume":"13","year":"2016","journal-title":"Nature Reviews Clinical Oncology"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","article-title":"Glycemic control in patients with insulinoma treated with everolimus","volume":"360","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10911-012-9268-y","article-title":"Targeting insulin and insulin-like growth factor signaling in breast cancer","volume":"17","year":"2012","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cmet.2013.02.008","article-title":"Duration of rapamycin treatment has differential effects on metabolism in mice","volume":"17","year":"2013","journal-title":"Cell Metabolism"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide inpatients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1126\/science.292.5522.1728","article-title":"Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB\u03b2)","volume":"292","year":"2001","journal-title":"Science"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","year":"2010","journal-title":"Lancet Oncology"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/db08-0792","article-title":"Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function","volume":"58","year":"2009","journal-title":"Diabetes"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref281","first-page":"2015","article-title":"Precipitation of autoimmune diabetes with anti immunotherapy","journal-title":"Diabetes Care"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1210\/jc.2006-1578","article-title":"Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets","volume":"92","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1345\/aph.1P651","article-title":"Ipilimumab: a novel treatment for metastatic melanoma","volume":"45","year":"2011","journal-title":"Annals of Pharmacotherapy"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/jgo.2017.01.04","article-title":"Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies","volume":"8","year":"2017","journal-title":"Journal of Gastrointestinal Oncology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00125-005-1886-0","article-title":"Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signaling and the effects of a selective glycogen synthase kinase-3 inhibitor","volume":"48","year":"2005","journal-title":"Diabetologia"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide inpatients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref71","article-title":"Insulin receptor signaling in normal and insulin-resistant states","volume":"6","year":"2014","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies","volume":"13","year":"2017","journal-title":"Nature Reviews Endocrinology"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","year":"2002","journal-title":"European Journal of Endocrinology"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/13543784.2016.1142531","article-title":"Tyrosine kinase inhibitors under investigation for the treatment oftype II diabetes","volume":"25","year":"2016","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","year":"2015","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1078155210378913","article-title":"Effect of the tyrosinekinaseinhibitors (sunitinib, sorafenib, dasatinib, andimatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice","volume":"17","year":"2011","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(20010715)92:2<207::AID-CNCR1311>3.0.CO;2-D","article-title":"Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854","volume":"92","year":"2001","journal-title":"Cancer"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"ref1171","first-page":"1","article-title":"Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances","volume":"5","year":"2016","journal-title":"Oncolytic Virotherapy"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cellbi.2006.08.006","article-title":"Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro","volume":"30","year":"2006","journal-title":"Cell Biology International"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2119\/2005-00029.Saltiel","article-title":"Insulin signaling and the regulation of glucose transport","volume":"10","year":"2004","journal-title":"Molecular Medicine"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cellbi.2006.08.006","article-title":"Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro","volume":"30","year":"2006","journal-title":"Cell Biology International"},{"key":"ref521","first-page":"1","article-title":"Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances","volume":"5","year":"2016","journal-title":"Oncolytic Virotherapy"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2004-0921","article-title":"Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance","volume":"146","year":"2005","journal-title":"Endocrinology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","year":"2003","journal-title":"Journal of Experimental Medicine"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiology","volume":"4","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1159\/000480634","article-title":"Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management","volume":"10","year":"2017","journal-title":"Case Reports in Oncology"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2337\/dc12-0002","article-title":"Diabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","year":"2010","journal-title":"Lancet Oncology"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combinationof everolimus with trastuzumab plus paclitaxel as first-line treatment for patients withHER2- positive advanced breast cancer (BOLERO-1): a phase 3, randomised, doubleblind, multicentre trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1073\/pnas.0803047105","article-title":"Disruption of Tsc2 in pancreatic beta cellsinduces beta cell mass expansion and improved glucose tolerance in a TORC1-dependentmanner","volume":"105","year":"2008","journal-title":"PNAS"},{"key":"ref721","article-title":"Insulin receptor signaling in normal and insulin-resistant states","volume":"6","year":"2014","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","year":"2004","journal-title":"Neuroendocrinology"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.2147\/OTT.S164574","article-title":"Adenosqaumous carcinoma of the lung","volume":"11","year":"2018","journal-title":"OncoTargets and Therapy"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?","volume":"39","year":"2009","journal-title":"European Journal of Clinical Investigation"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/db08-0792","article-title":"Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function","volume":"58","year":"2009","journal-title":"Diabetes"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","year":"2010","journal-title":"Diabetes"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","year":"2016","journal-title":"Future Oncology"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4158\/EP.12.4.358","article-title":"Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients","volume":"12","year":"2006","journal-title":"Endocrine Practice"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1159\/000480634","article-title":"Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management","volume":"10","year":"2017","journal-title":"Case Reports in Oncology"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/13543784.2016.1142531","article-title":"Tyrosine kinase inhibitors under investigation for the treatment oftype II diabetes","volume":"25","year":"2016","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.CCR-08-1253","article-title":"Mechanism and management of AKT inhibitor-induced hyperglycemia","volume":"15","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","year":"2003","journal-title":"Clinical Science"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/jgo.2017.01.04","article-title":"Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies","volume":"8","year":"2017","journal-title":"Journal of Gastrointestinal Oncology"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1002\/jcp.26539","article-title":"Targeting thephosphatidylinositol 3-kinase\/Akt\/mechanistic target of rapamycinsignaling pathway in B-lineage acute lymphoblastic leukemia: an update","volume":"233","year":"2018","journal-title":"Journal of Cellular Physiology"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2337\/dc12-0002","article-title":"Diabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","article-title":"Glycemic control in patients with insulinoma treated with everolimus","volume":"360","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.2147\/OTT.S164574","article-title":"Adenosqaumous carcinoma of the lung","volume":"11","year":"2018","journal-title":"OncoTargets and Therapy"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine Side Effects Induced by Immune Checkpoint Inhibitors","volume":"98","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1753-0407.12090","article-title":"Glucocorticoid-induced hyperglycemia","volume":"6","year":"2014","journal-title":"Journal of Diabetes"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1074-7613(00)80392-1","article-title":"The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD","volume":"7","year":"1997","journal-title":"Immunity"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1002\/jcp.26539","article-title":"Targeting thephosphatidylinositol 3-kinase\/Akt\/mechanistic target of rapamycinsignaling pathway in B-lineage acute lymphoblastic leukemia: an update","volume":"233","year":"2018","journal-title":"Journal of Cellular Physiology"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2017.02.001","article-title":"Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges","volume":"30","year":"2017","journal-title":"Drug Resistance Updates"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1126\/science.292.5522.1728","article-title":"Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB\u03b2)","volume":"292","year":"2001","journal-title":"Science"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1753-0407.12090","article-title":"Glucocorticoid-induced hyperglycemia","volume":"6","year":"2014","journal-title":"Journal of Diabetes"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer","volume":"8","year":"2009","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(20010715)92:2<207::AID-CNCR1311>3.0.CO;2-D","article-title":"Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854","volume":"92","year":"2001","journal-title":"Cancer"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.CCR-08-1253","article-title":"Mechanism and management of AKT inhibitor-induced hyperglycemia","volume":"15","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","article-title":"Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice","volume":"105","year":"2008","journal-title":"PNAS"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer","volume":"8","year":"2009","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd4476","article-title":"The immune checkpoint inhibitors: where are we now?","volume":"13","year":"2014","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","year":"2010","journal-title":"Diabetes"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","article-title":"Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice","volume":"105","year":"2008","journal-title":"PNAS"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1345\/aph.1P651","article-title":"Ipilimumab: a novel treatment for metastatic melanoma","volume":"45","year":"2011","journal-title":"Annals of Pharmacotherapy"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","year":"2015","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","year":"2003","journal-title":"Clinical Science"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1055-9965.EPI-06-0410","article-title":"A meta-analysis of diabetes mellitus and the risk of prostate cancer","volume":"15","year":"2006","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2017.02.001","article-title":"Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges","volume":"30","year":"2017","journal-title":"Drug Resistance Updates"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/db07-0922","article-title":"mTOR inhibition by rapamycin prevents betacelladaptation tohyperglycemia and exacerbates the metabolic state in type 2 diabetes","volume":"57","year":"2008","journal-title":"Diabetes"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with the use of mTOR inhibitors for cancer therapy","volume":"40","year":"2014","journal-title":"Cancer Treatment Reviews"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cmet.2013.02.008","article-title":"Duration of rapamycin treatment has differential effects on metabolism in mice","volume":"17","year":"2013","journal-title":"Cell Metabolism"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","year":"2004","journal-title":"Neuroendocrinology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4158\/EP.12.4.358","article-title":"Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients","volume":"12","year":"2006","journal-title":"Endocrine Practice"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040620715625966","article-title":"The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia","volume":"7","year":"2016","journal-title":"Therapeutic Advances in Hematology"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","year":"2003","journal-title":"Journal of Experimental Medicine"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreaticneuroendocrine","volume":"364","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"ref701","first-page":"173","article-title":"Incidence of endocrine dysfunction following the use of different inhibitor regimens: a systematic review and meta-analysis","volume":"4","year":"2018","journal-title":"JAMA"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine Side Effects Induced by Immune Checkpoint Inhibitors","volume":"98","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12032-013-0805-3","article-title":"Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer","volume":"31","year":"2014","journal-title":"Medical Oncology"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1210\/jc.2006-1578","article-title":"Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets","volume":"92","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MOT.0b013e32835a4be2","article-title":"Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use","volume":"17","year":"2012","journal-title":"Current Opinion in Organ Transplantation"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?","volume":"39","year":"2009","journal-title":"European Journal of Clinical Investigation"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/db05-1220","article-title":"Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4","volume":"55","year":"2006","journal-title":"Diabetes"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1055-9965.EPI-06-0410","article-title":"A meta-analysis of diabetes mellitus and the risk of prostate cancer","volume":"15","year":"2006","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA\u20114andanti\u2011PD\u20111antibodies alone and in combination","volume":"13","year":"2016","journal-title":"Nature Reviews Clinical Oncology"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","year":"2016","journal-title":"Future Oncology"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies","volume":"13","year":"2017","journal-title":"Nature Reviews Endocrinology"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2009.04.003","article-title":"The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review","volume":"156","year":"2009","journal-title":"Regulatory Peptides"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10911-012-9268-y","article-title":"Targeting insulin and insulin-like growth factor signaling in breast cancer","volume":"17","year":"2012","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/db05-1220","article-title":"Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4","volume":"55","year":"2006","journal-title":"Diabetes"}],"container-title":["Journal of Molecular Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/jme.bioscientifica.com\/view\/journals\/jme\/62\/2\/JME-18-0002.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jme.bioscientifica.com\/downloadpdf\/journals\/jme\/62\/2\/JME-18-0002.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:53:29Z","timestamp":1784555609000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/jme\/article\/62\/2\/R187-R199\/14362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":130,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/jme-18-0002","relation":{},"ISSN":["0952-5041","1479-6813"],"issn-type":[{"value":"0952-5041","type":"print"},{"value":"1479-6813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}